Lexaria Secures Five New Patents in Japan and Australia, Two for GLP-1 Diabetes
Lexaria Bioscience secured five new patents in Japan and Australia, including two for GLP-1 diabetes using its DehydraTECH platform, bringing its global count to 65 granted patents. The new patents cover Japanese hypertension through 2043, Australian epilepsy through 2044 and Australian diabetes through 2044.
1. Patent Awards Overview
Lexaria Bioscience announced the award of five additional patents as part of its ongoing R&D efforts, reflecting continued expansion of its global intellectual property portfolio. These grants follow recent Phase 1b human study results in Australia highlighting the performance of its DehydraTECH drug delivery platform.
2. Details of Patent Families
The company received two Japanese patents (7823051, 7823052) for hypertension expiring April 25, 2043; one Australian patent (2024205127) for epilepsy expiring February 20, 2044; and two Australian patents (2025205229, 2024394427) for diabetes treatments with GLP-1 drugs expiring December 3, 2044.
3. Strategic Impact
These new grants boost Lexaria’s total to 65 worldwide patents, strengthening its position in the competitive GLP-1 industry and enhancing its bargaining power for partnerships and licensing opportunities in key markets.